Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$77M
1 round on record
Latest round
$77M
Series A · Jan 2021 · 5 yr ago
Team
51-200
employees, estimated range
Backers
1
Nextech Invest
The money's age
Long since its last round
68 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jan 4, 2021
Raised a round Series A $77M
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series A | Jan 2021 | $77M | — | bioworld.com |
Backed byfrom the funds' portfolios and accelerator catalogs
Nextech Invest Similar startupsby what they do, their industry and backers
Autolus is a CAR T cell therapy company which develops advanced autologous T cell therapies that have the potential to deliver…
At ITM, precision drives everything - from isotope manufacturing to cancer treatment—improving outcomes and delivering what patients and…
Discover cutting-edge therapies by enrolling in clinical trials. Power helps patients everywhere take control of their care.
Alia Therapeutics is a startup which is developing next-generation gene editing medicines to cure genetic diseases.
Unlocking the diversity of biological life to accelerate sustainable development.
Committed to developing high-impact and differentiated therapies, with a focus on building a robust autoimmune disease and cancer pipeline…
News
Report
Dustin Wright
Dustin Wright is Vice President of Clinical Operations at IconOVir. He brings over 20 years of experience across all phases of drug development in pharmaceutical and biotechnology organizations. Prior to joining IconOVir, he was Senior Director, Clinical
Read more
Report
IconOVir Bio Announces First Patient Dosed in Phase 1 Clinical Trial of its Lead Product Candidate, ICVB-1042
- ICVB-1042 is an oncolytic adenovirus for the treatment of advanced solid tumors -- Initial safety data expected in 2H 2023, followed by proof-of-concept data in 2024 - SAN DIEGO, CA., July 11, 2023 - IconOVir Bio, Inc. (IconOVir), a clinical-stage biote
Read more
Report
IconOVir Bio to Present at Jefferies Healthcare Conference
SAN DIEGO, CA., May 31, 2023 - IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced that Mark McCamish, M.
Read more
Report
IconOVir Bio to Present at Oppenheimer 33rd Annual Healthcare Conference
SAN DIEGO, CA., March 7, 2023 - IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced that Mark McCamish, M
Read more
Report
IconOVir Announces New Preclinical Data Showcasing Best-in-Class Potential of ICVB-1042, its Lead Oncolytic Virus, at SITC 2022
- ICVB-1042 demonstrates selective replication, broad tropism and anti-tumor activity across multiple in vitro and in vivo models - - Proprietary Ad5/Ad34 mutation improves viral entry into target tumor cells, enhancing tropism - - On track to initiate Ph
Read more
Report
PharmiWeb.com - Thank you
After twenty-five years, PharmiWeb.com is closing. A note of thanks to the pharmaceutical industry community that built it.
Read more
Report
Julie Maltzman, M.D.
Dr. Julie Maltzman is a medical oncologist with broad experience built over 20 years across all phases of drug development. She joined IconOVir in Oct 2022 from a VP, Global Head of GI Cancers and Cancer Immunotherapy role at Roche/Genentech. There, Dr. M
Read more
Report
IconOVir Bio Appoints Julia Maltzman, M.D., as Chief Medical Officer
SAN DIEGO, CA., Oct. 10, 2022 - IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced the appointment of Ju
Read more
Report
Show more news
Financials
Total raised
$77M
Latest round
Series A
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series A | 2021 | $77M | Details |